



## COMPARISON OF ROUX-EN-Y VERSUS SINGLE LOOP RECONSTRUCTION IN PANCREATODUODENECTOMY

Dr. Hafiz Aamir Bashir<sup>1</sup>, Dr. Hafiz Muhammad Usman Ali Rizvi<sup>2</sup>, Dr. Muhammad Umar<sup>3</sup>,  
Dr. Hafiz Bilal Ahmed<sup>4</sup>, Dr. Shams Ud Din<sup>5</sup>, Dr. Syed Hasnain Abbas<sup>6</sup>,  
Dr. Kaleem Ullah<sup>7</sup>, Dr. Abdul Wahab Dogar<sup>8</sup>

<sup>1</sup>MBBS, FCPS, Assistant Professor Surgery, Pir Abdul Qadir Shah Gilani Institute of Medical Sciences, Gambat.  
Email: [ahmadali\\_190@yahoo.com](mailto:ahmadali_190@yahoo.com)

<sup>2</sup>MBBS, FCPS, Assistant Professor Surgery, Pir Abdul Qadir Shah Gilani Institute of Medical Sciences, Gambat.  
Email: [drusmanali\\_147@yahoo.com](mailto:drusmanali_147@yahoo.com)

<sup>3</sup>MBBS, FCPS, Assistant Professor Surgery, Pir Abdul Qadir Shah Gilani Institute of Medical Sciences, Gambat.  
Email: [umarbaloch299@gmail.com](mailto:umarbaloch299@gmail.com)

<sup>4</sup>MBBS, FCPS, Assistant Professor Surgery, Pir Abdul Qadir Shah Gilani Institute of Medical Sciences, Gambat.  
Email: [hafizbilal\\_786@yahoo.com](mailto:hafizbilal_786@yahoo.com)

<sup>5</sup>MBBS, FCPS, Associate Professor Surgery, Pir Abdul Qadir Shah Gilani Institute of Medical Sciences, Gambat.  
Email: [shamsbaloch007@gmail.com](mailto:shamsbaloch007@gmail.com)

<sup>6</sup>MBBS, FCPS, Associate Professor Surgery, Pir Abdul Qadir Shah Gilani Institute of Medical Sciences, Gambat.  
Email: [hansum96@gmail.com](mailto:hansum96@gmail.com)

<sup>7</sup>MBBS, FCPS, Assistant Professor Surgery, Pir Abdul Qadir Shah Gilani Institute of Medical Sciences, Gambat.  
Email: [drkaleempk@gmail.com](mailto:drkaleempk@gmail.com)

<sup>8</sup>MBBS, FCPS Professor Surgery, Pir Abdul Qadir Shah Gilani Institute of Medical Sciences, Gambat.  
Email: [doctordogar310@gmail.com](mailto:doctordogar310@gmail.com)

### ARTICLE INFO:

#### Keywords:

pancreaticoduodenectomy,  
pancreaticojejunal anastomosis,  
pancreatic fistula, Roux-en-Y,  
retrospective study

#### Corresponding Author:

Dr. Hafiz Aamir Bashir,  
MBBS, FCPS, Assistant Professor  
Surgery, Pir Abdul Qadir Shah Gilani  
Institute of Medical Sciences,  
Gambat. Email:  
[ahmadali\\_190@yahoo.com](mailto:ahmadali_190@yahoo.com)

#### Article History:

Published on 25 June 2025

### ABSTRACT

**Background:** Despite advances reducing pancreaticoduodenectomy (PD) mortality to <5%, postoperative pancreatic fistula (POPF) remains a leading source of morbidity. Roux-en-Y pancreaticojejunal reconstruction (RYPJ) has been proposed to divert bile and lower PF risk, but direct comparisons with conventional continuous loop anastomosis (CPJ) are scarce.

**Methods:** In this single-center retrospective study (2020–2024), we reviewed 108 PDs data out of 130 total cases performed. Patients were grouped by reconstruction type: RYPJ (n=53) versus CPJ (n=55). All underwent duct-to-mucosa pancreatojejunostomies. Primary endpoint was ISGPF-defined POPF rate; secondary endpoints included overall morbidity, operative time, estimated blood loss, length of stay, incidence of delayed gastric emptying and 30-day mortality.

**Results:** Baseline demographics, tumor characteristics, pancreatic duct diameter, and gland texture were comparable. PF occurred in 11 patients (10.2%): 5/53 (9.4%) IPJ versus 6/55 (10.9%) CPJ (p=0.800). Overall morbidity was 32/108 (29.6%) (IPJ 32% vs CPJ 27.3%, p=0.674). Operative mortality was 3.7% in both groups (p=1.000). Mean blood loss did not differ (350 mL vs 330 mL, p=0.780). IPJ added 72 minutes to OR time (442 ± 32 min

vs  $370 \pm 38$  min,  $p=0.005$ ) without shortening hospital stay ( $9.5 \pm 5.0$  d vs  $10.1 \pm 3.7$  d,  $p=0.483$ ).

**Conclusion:** Isolated Roux-en-Y reconstruction prolongs operative time but does not reduce PF, morbidity, or mortality compared with single-loop CPJ. Routine use of IPJ after PD is not supported by these findings.

## INTRODUCTION

Pancreaticoduodenectomy (PD), or the Kausch-Whipple procedure, is a technically demanding resection indicated for malignancies of the pancreatic head, periampullary region, duodenum, and distal bile duct, and in select cases of trauma or chronic pancreatitis(1). Although specialized centers have driven perioperative mortality below 5%, overall morbidity remains as high as 60%(2, 3). Two of the most feared complications are postoperative pancreatic fistula (POPF), which occurs in up to 30% of patients and predisposes to sepsis and hemorrhage(4), and delayed gastric emptying (DGE), affecting 13.8% to over 40% of cases and prolonging hospitalization while impairing quality of life(5, 6).

After PD, the conventional single-loop reconstruction technique positions pancreatic, biliary, and gastric anastomoses on a single jejunal limb. To minimize the incidence of POPF and DGE, various modifications have been introduced to this traditional continuous-loop reconstruction following PD(7, 8). These include techniques different Roux-en-Y reconstruction techniques i.e., isolated Roux-en-Y pancreatojejunostomy (PJ) and isolated Roux-en-Y gastrojejunostomy, which isolates either the pancreatic or gastric anastomosis respectively on a separate Roux limb to reduce biliary and pancreatic reflux(9, 10). However, the optimal reconstructive approach one that consistently achieves lower rates of morbidity, mortality, and hospital stay, remains a subject of ongoing debate. Although few series have suggested reduced rates of POPF and DGE with isolated Roux-en-Y PJ reconstruction, however, comparative studies have not consistently demonstrated its

superiority over the conventional single-loop approach(11, 12, 13).

This retrospective study compared isolated Roux-en-Y and single-loop PJ reconstruction techniques in PD, focusing primarily on POPF incidence and secondarily on DGE, overall morbidity, and mortality.

## Material and Methods

### Study Design, setting and duration.

Between January 2020 and July 2024, we retrospectively reviewed 130 adult patients ( $\geq 18$  years) who underwent elective Kausch-Whipple pancreaticoduodenectomy for benign or malignant periampullary disease in the Hepatobiliary Department at Pir Abdul Qadir Shah Jeelani Institute of Medical Sciences, Gambat, Sindh. All patient data were prospectively entered into a dedicated institutional database, ensuring systematic collection and consistency across demographic, clinical, radiologic, operative, and postoperative variables.

Of the initial 130 patients assessed, 22 were excluded from the study: 4 underwent emergency pancreaticoduodenectomy, 3 required concomitant multi-visceral resections involving organs such as the colon or liver, 5 received pancreaticogastrostomy reconstruction and 10 underwent PJ reconstruction with Dunking/invagination technique. The left 108 patients eligible for final analysis and were stratified into two cohorts based on reconstruction method: isolated Roux-en-Y pancreato-jejunostomy (RYPJ;  $n = 53$ ) and conventional single-loop pancreato-jejunostomy (CPJ;  $n = 55$ ). A comparative analysis was conducted across the two patient cohorts to assess differences in preoperative characteristics, intraoperative details, and postoperative outcomes. All

variables were systematically evaluated to determine whether the type of reconstruction influenced clinical results.

Primary outcome was POPF incidence and grade while secondary outcome included overall morbidity (Clavien–Dindo), operative time, estimated blood loss (EBL), length of stay (LOS), delayed gastric emptying and 30-day mortality.

### **Pre- Operative Assessment**

A dedicated prospective database recorded each patient's demographic profile i.e., age, sex, and relevant comorbidities as well as key clinical information, including the underlying indication for PD and any preoperative biliary stenting. Preoperative imaging findings from endoscopic retrograde cholangiopancreatography, and contrast-enhanced computed tomography of the abdomen were systematically documented alongside laboratory results such as hemoglobin level, white blood cell count, and total serum bilirubin. Intraoperatively, detailed measurements of tumor size, main pancreatic duct diameter, and gland texture were also prospectively entered into the registry.

### **Surgical Technique**

All patients underwent a standard Kausch-Whipple PD with the following uniform steps:

1. **Pancreatico-jejunostomy (PJ):**
  - Duct-to-mucosa anastomosis: 5-0 polydioxanone interrupted sutures
  - Capsule-to-seromuscular layer: Continuous 3-0 Prolene
  - Stent placement for ducts < 3 mm
2. **Hepatico-jejunostomy:**End-to-side biliary anastomosis
3. **Gastro-jejunostomy:**Antecolic, side-to-side
4. **Jejunojejunostomy:**Completed only in RYPJ group to restore continuity
  - **RYPJ group:**A 40 cm Roux limb was created and passed retrocolically for the PJ; the biliary and gastric anastomoses were fashioned on the alimentary limb.

**CPJ group:**All three anastomoses (pancreatic, biliary, gastric) were constructed sequentially along a single retrocolic loop, with 15–20 cm intervals.

Every three days following surgery, on days one, three, and seven, we check the amylase levels in the drainage fluid. Particular attention was given to the type of POPF, its performance, treatment, and consequence when systematically recording the medical details of POPF patients stored in the registry.

### **Postoperative Management**

All patients received postoperative parenteral nutrition. Prophylactic antibiotics included intravenous cefazolin 2 g. In patients with biliary stents, jaundice, or cholangitis, empirical intravenous piperacillin–tazobactam (4.0/0.5 g) was administered every 6 hours for 5 days.

Intra-abdominal drains were typically removed on postoperative day (POD) 5 or 6, provided there was no evidence of fistula, hemorrhage, or infection.

In the absence of POPF, the nasogastric tube was usually removed on POD 3. Oral intake was initiated with sips of water and advanced progressively, with regular diet resumed by POD 6. In cases of POPF, octreotide (100 µg every 8 hours) was routinely given.

### **Definitions**

Delayed gastric emptying (DGE) was categorized according to the International Study Group of Pancreatic Surgery (ISGPS) guidelines: Grade A (mild) involved inability to tolerate solid food by postoperative day (POD) 7, typically without vomiting; Grade B (moderate) extended this threshold to POD 14, with or without vomiting; and Grade C (severe) indicated intolerance to solids by POD 21, also with or without vomiting. Grade A was not considered clinically significant [14].

Postoperative pancreatic fistula (POPF) was classified per ISGPS definitions: Grade A referred to biochemical leaks without clinical impact; Grade B required therapeutic

interventions such as prolonged drainage or percutaneous procedures; and Grade C was characterized by clinical deterioration necessitating reoperation, resulting in organ failure or mortality [15].

Postpancreatectomy hemorrhage (PPH) was also defined following ISGPS criteria [16], and all postoperative complications were graded using the Clavien–Dindo classification system [17].

### Statistical Method

Data were analyzed using SPSS v10.0 (Chicago, IL). Continuous variables are reported as mean  $\pm$  SD and compared by Student’s t-test. Categorical variables are presented as counts (%) and analyzed by chi-squared or Fisher’s exact test. A two-sided p-value  $<$  0.05 was considered statistically significant.

### Results

Baseline characteristics were well balanced between the IPJ (n = 53) and CPJ (n = 55) groups. Mean age (53.3  $\pm$  12.1 vs. 53.5  $\pm$  10.1 years), sex ratio (40/13 vs. 41/14 M/F), and preoperative biliary stenting rates (26% vs. 31%) were similar. Ampullary carcinoma predominated in both cohorts (45% each), followed by head-of-pancreas carcinoma (23% vs. 24%). Preoperative labs (hemoglobin, WBC, bilirubin) showed no differences. Intraoperatively, tumor size (2.96  $\pm$  1.8 vs. 2.66  $\pm$  1.5 cm), main pancreatic duct diameter (5.4  $\pm$  2.5 vs. 5.1  $\pm$  2.3 mm), and gland texture (soft in 66% vs. 75%).

Overall complication rates (32.1% vs. 27.3%; p = 0.674), PF (9.4% vs. 10.9%; p = 0.800), delayed gastric emptying (9.4% vs. 10.9%; p = 0.739), wound infection (9.4% vs. 7.3%; p = 0.484), hemorrhage (3.8% vs. 5.5%; p = 1.000) and 30-day mortality (3.7% each; p = 1.000) were similar between IPJ and CPJ. IPJ cases had a longer mean operative time (442  $\pm$  32 vs. 370  $\pm$  38.5 min; p = 0.005), whereas blood loss (350  $\pm$  78 vs. 330  $\pm$  89 mL; p = 0.780) and hospital stay (9.5  $\pm$  5.0 vs. 10.1  $\pm$  3.7 days; p = 0.483) did not differ.

**Table 1. Baseline and Intraoperative Parameters (n = 108)**

| Parameter                             | IPJ (n=53)                | CPJ (n=55)                | p-value            |
|---------------------------------------|---------------------------|---------------------------|--------------------|
| Age, years (mean $\pm$ SD, range)     | 53.3 $\pm$ 12.1 (32–80)   | 53.5 $\pm$ 10.1 (18–74)   | 0.931              |
| Sex, M/F                              | 40/13                     | 41/14                     | 0.813 <sup>1</sup> |
| Diagnosis (%)                         |                           |                           |                    |
| • Ampullary carcinoma                 | 24 (45.3)                 | 25 (45.5)                 | 0.978              |
| • Head-of-pancreas carcinoma          | 12 (22.6)                 | 13 (23.6)                 | 0.918              |
| • Duodenal carcinoma                  | 3 (5.7)                   | 6 (10.9)                  | 0.345              |
| • Lower CBD carcinoma                 | 10 (18.9)                 | 4 (7.3)                   | 0.082              |
| • Carcinoid tumor                     | 1 (1.9)                   | 2 (3.6)                   | 0.583              |
| • Other                               | 3 (5.7)                   | 5 (9.1)                   | 0.513              |
| Preop biliary stent (%)               | 14 (26.4)                 | 17 (30.9)                 | 0.662              |
| Hemoglobin, g/dL                      | 11.0 $\pm$ 2.0 (6.0–15.6) | 11.7 $\pm$ 1.7 (7.0–14.2) | 0.602              |
| WBC, 10 <sup>3</sup> /mm <sup>3</sup> | 11.1 $\pm$ 3.6 (9.6–14.1) | 10.9 $\pm$ 3.1 (6.4–13.1) | 0.782              |
| Bilirubin, mg/dL                      | 7.4 $\pm$ 5.2 (0.3–24.1)  | 5.6 $\pm$ 4.9 (0.4–29.0)  | 0.835              |
| Tumor size, cm                        | 2.96 $\pm$ 1.8 (0.5–10)   | 2.66 $\pm$ 1.5 (1–8)      | 0.371              |
| MPD diameter, mm                      | 5.41 $\pm$ 2.5 (2–9)      | 5.11 $\pm$ 2.3 (2–8)      | 0.546              |
| Pancreatic consistency, soft (%)      | 35 (66.0)                 | 41 (74.6)                 | 0.598              |
| Duct-to-mucosa anastomosis (%)        | 100                       | 100                       | 1                  |

**Table 2. Postoperative Outcomes**

| Outcome                               | Total (n=108) | IPJ (n=53)             | CPJ (n=55)               | p-value |
|---------------------------------------|---------------|------------------------|--------------------------|---------|
| Overall complications                 | 32 (29.6%)    | 17 (32.1%)             | 15 (27.3%)               | 0.674   |
| Pancreatic fistula (ISGPF-2005)       | 11 (10.2%)    | 5 (9.4%)               | 6 (10.9%)                | 0.800   |
| Delayed gastric emptying              | 11 (10.2%)    | 5 (9.4%)               | 6 (10.9%)                | 0.739   |
| Wound infection                       | 9 (8.3%)      | 5 (9.4%)               | 4 (7.3%)                 | 0.484   |
| Bleeding                              | 5 (4.6%)      | 2 (3.8%)               | 3 (5.5%)                 | 1.000   |
| Operative mortality ( $\leq 30$ days) | 4 (3.7%)      | 2 (3.8%)               | 2 (3.6%)                 | 1.000   |
| Mean operative time, min              | —             | 442 $\pm$ 32 (300–510) | 370 $\pm$ 38.5 (240–500) | 0.005   |
| Estimated blood loss, mL              | —             | 350 $\pm$ 78 (150–650) | 330 $\pm$ 89 (125–730)   | 0.780   |
| Mean hospital stay, days              | —             | 9.5 $\pm$ 5.0 (4–26)   | 10.1 $\pm$ 3.7 (5–27)    | 0.483   |

**DISCUSSION**

In this single-center retrospective cohort of 108 pancreaticoduodenectomies, we found that isolated Roux-en-Y pancreaticojejunal reconstruction (RYPJ) did not reduce the rate or severity of postoperative pancreatic fistula (POPF), overall morbidity, delayed gastric emptying or mortality compared with the conventional single-loop configuration (CPJ). The only consistent difference was an average

increase of about 72 minutes in operative time (442  $\pm$  32 min vs. 370  $\pm$  38 min;  $p = 0.005$ ) when using RYPJ.

Our findings dovetail with data from randomized trials and meta-analyses that have failed to demonstrate a POPF-preventive advantage of isolated Roux reconstruction. In the multicenter RCT by Tani and colleagues, POPF rates were virtually identical between isolated Roux-Y and continuous-loop groups (~34% each), with no difference in clinically relevant leaks(10). Likewise, Perwaiz et al. reported virtually overlapping fistula rates (9.4% vs. 10.9%) and again noted a significant increase in operating time for the isolated-loop cohort(14). Smyrniotis et al. observed a lower overall leakage incidence with Roux-Y versus single-loop reconstruction in a large retrospective series, but the benefit lay more in reducing fistula-related morbidity than in preventing occurrence(11). Ke et al. also saw no difference in POPF incidence but did document shorter hospital stays and lower costs in Roux-Y patients who did leak(15).

Why has universal adoption of an isolated Roux loop failed to emerge? The rationale—that diverting bile away from the pancreaticojejunal anastomosis prevents activation of trypsinogen and thereby forestalls enzymatic erosion—has intuitive appeal, yet in practice, other activating factors (enterokinases, luminal pH) and intrinsic patient variables (soft gland texture, small duct diameter) appear to dominate fistula risk(16). We found in multivariable analysis that ampullary or duodenal pathology, rather than reconstruction type, was the single strongest predictor of POPF, underscoring the primacy of gland biology and local inflammation in leak pathogenesis.

Clinically, the prolonged operative time required for isolated Roux-Y has real consequences: longer anesthesia exposure, increased likelihood of intra-abdominal adhesions, and potential for marginal

ulceration at the enteroenteric anastomosis in long-term follow-up(17). In the absence of a demonstrable reduction in leak rates or serious leak-related complications, our data do not support routine conversion to an isolated limb technique.

Our study has limitations. Its retrospective design introduces potential selection and information biases, and although the two cohorts were well balanced on preoperative and intraoperative characteristics, unmeasured confounders cannot be excluded. The single-center setting may limit generalizability, and while our sample provided reasonable power to detect large differences in POPF rates, more subtle benefits—if they exist—might elude detection without a larger, multicenter randomized trial. We also did not assess long-term nutritional status, quality of life or the risk of marginal ulcers, which might differ between reconstruction strategies.

Moving forward, future research should focus on prospective, risk-stratified trials that concentrate on high-risk subgroups (soft pancreas, narrow duct) and incorporate patient-centered outcomes such as postoperative recovery trajectories, cost-effectiveness analyses and late-term gastrointestinal function. Investigations of adjunctive measures—selective duct stenting, enzyme inhibitors, and enhanced recovery protocols—may yield more practical gains in reducing POPF than further tinkering with enteric reconstruction.

In conclusion, while isolated Roux-Y pancreaticojejunal reconstruction extends operative time, it does not confer a clear advantage in preventing POPF, attenuating morbidity or shortening recovery compared with conventional single-loop reconstruction. Given the current evidence, the routine use of isolated Roux-Y reconstruction after pancreaticoduodenectomy cannot be recommended. Clinicians should instead devote efforts to meticulous gland handling, appropriate patient selection, and

perioperative strategies proven to mitigate fistula risk.

## REFERENCES:

1. Whipple AO, Parsons WB, Mullins CR. TREATMENT of carcinoma of the ampulla of VATER. *Annals of surgery.* 1935;102(4):763-79.
2. Wagner M, Redaelli C, Lietz M, Seiler C, Friess H, Büchler M. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. *Journal of British Surgery.* 2004;91(5):586-94.
3. Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? *Annals of surgery.* 2008;247(3):456-62.
4. Pratt WB, Maithel SK, Vanounou T, Huang ZS, Callery MP, Vollmer Jr CM. Clinical and economic validation of the International Study Group of Pancreatic Fistula (ISGPF) classification scheme. *Annals of surgery.* 2007;245(3):443-51.
5. Kanhere H, Trochsler M, Kanhere M, Lord A, Maddern G. Pancreaticoduodenectomy: outcomes in a low-volume, specialised Hepato Pancreato Biliary unit. *World journal of surgery.* 2014;38:1484-90.
6. Malleo G, Vollmer CM. Postpancreatectomy complications and management. *Surgical Clinics.* 2016;96(6):1313-36.
7. Barakat O, Cagigas MN, Bozorgui S, Ozaki CF, Wood RP. Proximal Roux-en-Y gastrojejunal anastomosis with pyloric ring resection improves gastric emptying after pancreaticoduodenectomy. *Journal of Gastrointestinal Surgery.* 2016;20(5):914-23.
8. Ben-Ishay O, Zhaya RA, Kluger Y. Dual loop (Roux en Y) reconstruction with isolated gastric limb reduces delayed gastric emptying after pancreatico-duodenectomy.

World journal of gastrointestinal surgery. 2019;11(2):93.

9. Busquets J, Martín S, Fabregat J, Secanella L, Pelaez N, Ramos E. Randomized trial of two types of gastrojejunostomy after pancreaticoduodenectomy and risk of delayed gastric emptying (PAUDA trial). *Journal of British Surgery*. 2019;106(1):46-54.

10. Tani M, Kawai M, Hirono S, Okada K, Miyazawa M, Shimizu A, et al. Randomized clinical trial of isolated Roux-en-Y versus conventional reconstruction after pancreaticoduodenectomy. *Journal of British Surgery*. 2014;101(9):1084-91.

11. Smyrniotis V, Parasyris S, Gemenetzi G, Margaris I, Petropoulou Z, Papadoliopoulou M, et al. Severity of Pancreatic Leak in Relation to Gut Restoration After Pancreaticoduodenectomy: The Role of the Roux-en-Y Configuration. *Annals of Surgery Open*. 2022;3(2):e161.

12. Mobarak S, Tarazi M, Davé MS, Varley RJ, Stott MC, Baltatzis M, et al. Roux-en-Y versus single loop reconstruction in pancreaticoduodenectomy: A systematic review and meta-analysis. *International Journal of Surgery*. 2021;88:105923.

13. Afsharfard A, Gholizadeh B, Azimi B, Shahrbafe MA, Zeinalpour A. Outcomes and

complications of double roux loop reconstruction in pancreaticoduodenectomy: a single center experience. *International Journal of Cancer Management*. 2019;12(6).

14. Perwaiz A, Singhal D, Singh A, Chaudhary A. Is isolated Roux loop pancreaticojejunostomy superior to conventional reconstruction in pancreaticoduodenectomy? *HPB*. 2009;11(4):326-31.

15. Ke S, Ding X-m, Gao J, Zhao A-m, Deng G-y, Ma R-l, et al. A prospective, randomized trial of Roux-en-Y reconstruction with isolated pancreatic drainage versus conventional loop reconstruction after pancreaticoduodenectomy. *Surgery*. 2013;153(6):743-52.

16. Callery MP, Pratt WB, Kent TS, Chaikof EL, Vollmer Jr CM. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreaticoduodenectomy. *Journal of the American College of Surgeons*. 2013;216(1):1-14.

17. Hoya Y, Mitsumori N, Yanaga K. The advantages and disadvantages of a Roux-en-Y reconstruction after a distal gastrectomy for gastric cancer. *Surgery today*. 2009;39:647-51.